<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37851042</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-6899</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Continuum (Minneapolis, Minn.)</Title><ISOAbbreviation>Continuum (Minneap Minn)</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases.</ArticleTitle><Pagination><StartPage>1538</StartPage><EndPage>1563</EndPage><MedlinePgn>1538-1563</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/CON.0000000000001345</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This article reviews the clinical spectrum of amyotrophic lateral sclerosis (ALS), its variant presentations, and the approach to diagnosis and management. This review includes a detailed discussion of current and emerging disease-modifying therapies and the management of respiratory and bulbar manifestations of disease. An updated review of ALS genetics and pathophysiology is also provided. This article also touches on several other important motor neuron diseases.</AbstractText><AbstractText Label="LATEST DEVELOPMENTS">A new set of simplified diagnostic criteria may help identify patients at earlier stages of the disease. A coformulation of sodium phenylbutyrate and tauroursodeoxycholic acid has been shown to have a significant benefit on disease progression and survival, leading to approval by regulatory authorities in the United States and Canada. An oral formulation of edaravone and an antisense oligonucleotide to a SOD1 gene variation (tofersen) have also recently been approved by the US Food and Drug Administration (FDA). Phase 3 trials of intrathecal mesenchymal stem cells failed to meet primary end points for efficacy. Updated American Academy of Neurology quality measures for the care of patients with ALS were published in 2023.</AbstractText><AbstractText Label="ESSENTIAL POINTS">There has been continued progress in ALS genetics, diagnosis, and disease-modifying therapies. However, we still lack a definitive biomarker or a treatment that can halt the progression or reverse the course of disease. The evolving understanding of the genetic and pathophysiologic underpinnings of disease offers promise for more effective and clinically meaningful treatments in the future.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Izenberg</LastName><ForeName>Aaron</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Continuum (Minneap Minn)</MedlineTA><NlmUniqueID>9509333</NlmUniqueID><ISSNLinking>1080-2371</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37851042</ArticleId><ArticleId IdType="doi">10.1212/CON.0000000000001345</ArticleId><ArticleId IdType="pii">00132979-202310000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41(2):118&#x2013;130. doi:10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener 2022 May;23(3-4):220&#x2013;225. doi:10.1080/21678421.2021.1949021</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1949021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014-2016. Amyotroph Lateral Scler Frontotemporal Degener 2022;23(5-6):378&#x2013;382. doi:10.1080/21678421.2021.2023190</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.2023190</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010;81(4):385&#x2013;390. doi:10.1136/jnnp.2009.183525</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo V, Bueno-De-Mesquita HB, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009;65(4):378&#x2013;385. doi:10.1002/ana.21653</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21653</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, Seelen M, de Jong SW, et al. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84(9):976&#x2013;981. doi:10.1136/jnnp-2012-304724</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId></ArticleIdList></Reference><Reference><Citation>Blecher R, Elliott MA, Yilmaz E, et al. Contact sports as a risk factor for amyotrophic lateral sclerosis: a systematic review. Global Spine J 2019;9(1):104&#x2013;118. doi:10.1177/2192568218813916</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568218813916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 2015;7:181&#x2013;193. doi: 10.2147/CLEP.S37505</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S37505</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, O&#x2019;Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005;64(1):32&#x2013;37. doi:10.1212/01.WNL.0000148649.17706.D9</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148649.17706.D9</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, et al. Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 2022y;21(5):480&#x2013;493. doi:10.1016/S1474-4422(21)00465-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Pioro EP. Laughter, crying and sadness in ALS. J Neurol Neurosurg Psychiatry 2017;88(10):825&#x2013;831. doi:10.1136/jnnp-2017-315622</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60(7):1094&#x2013;1097. doi:10.1212/01.wnl.0000055861.95202.8d</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000055861.95202.8d</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology 2019;93(10):e984&#x2013;e994. doi:10.1212/WNL.0000000000008063</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65(4):586&#x2013;590. doi:10.1212/01.wnl.0000172911.39167.b6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000172911.39167.b6</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis &#x2013; frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(3-4):153&#x2013;174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId></ArticleIdList></Reference><Reference><Citation>The Ohio State University Wexner Medical Center. Ohio State establishing national standards for ALS genetic testing, research and patient care. Accessed July 25, 2023. wexnermedical.osu.edu/departments/innovations/neuronews/alsguidelines</Citation></Reference><Reference><Citation>Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 2015;33(4):735&#x2013;748. doi:10.1016/j.ncl.2015.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66(5):647&#x2013;653. doi:10.1212/01.wnl.0000200962.94777.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000200962.94777.71</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry 2020;91(4):373&#x2013;377. doi:10.1136/jnnp-2019-322541</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Pasmantier M, Lee YW, Weimer L, Mitsumoto H. Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle Nerve 2013;47(1):28&#x2013;32. doi:10.1002/mus.23496</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23496</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011;82(7):740&#x2013;746. doi:10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009;73(20):1686&#x2013;1692. doi:10.1212/WNL.0b013e3181c1dea3</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1dea3</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM. Amyotrophic lateral sclerosis regional variants (brachial amyotrophic diplegia, leg amyotrophic diplegia, and isolated bulbar amyotrophic lateral sclerosis). Neurol Clin 2015;33(4):775&#x2013;785. doi:10.1016/j.ncl.2015.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009;72(12):1087&#x2013;1094. doi:10.1212/01.wnl.0000345041.83406.a2</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000345041.83406.a2</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam C, Scelsa SN, Macgowan DJ. The clinical course of progressive bulbar palsy. Amyotroph Lateral Scler 2010;11(4):364&#x2013;368. doi:10.3109/17482960903513159</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903513159</ArticleId></ArticleIdList></Reference><Reference><Citation>Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000;23(10):1488&#x2013;1502. doi:10.1002/1097-4598(200010)23:10&lt;1488::aid-mus4&gt;3.0.co;2-e</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-4598(200010)23:10&lt;1488::aid-mus4&gt;3.0.co;2-e</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabes J, Matthews L, Filippini N, Talbot K, Jenkinson M, Turner MR. Quantitative FLAIR MRI in amyotrophic lateral sclerosis. Acad Radiol 2017;24(10):1187&#x2013;1194. doi:10.1016/j.acra.2017.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2017.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeben B, Wilke C, Bender B, Ziemann U, Synofzik M. The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. J Neurol Sci 2019 15;406:116440. doi:10.1016/j.jns.2019.116440</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.116440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirian A, Korngut L. The utility of the laboratory work up at the time of diagnosis of amyotrophic lateral sclerosis. J Neuromuscul Dis 2018;5(1):35&#x2013;38. doi:10.3233/JND-170281</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JND-170281</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I, Janik P, Kwieci&#x144;ski H. Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes. Eur J Neurol 2004;11(1):13&#x2013;16. doi:10.1046/j.1351-5101.2003.00697.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1351-5101.2003.00697.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(5):293&#x2013;299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119(3):497&#x2013;503. doi:10.1016/j.clinph.2007.09.143</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020;131(8):1975&#x2013;1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannaford A, Pavey N, van den Bos M, et al. Diagnostic utility of Gold Coast criteria in amyotrophic lateral sclerosis. Ann Neurol 2021;89(5):979&#x2013;986. doi:10.1002/ana.26045</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26045</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 2018;17(1):94&#x2013;102. doi:10.1016/S1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. Familial versus sporadic amyotrophic lateral sclerosis&#x2013;a false dichotomy? Brain 2011;134(Pt 12):3429&#x2013;3431. doi:10.1093/brain/awr296</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr296</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17(1):17&#x2013;23. doi:10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Hardiman O, Al-Chalabi A, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol 2022;21(5):465&#x2013;479. doi:10.1016/S1474-4422(21)00414-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(21)00414-2</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Henden L, Fifita JA, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet 2020;14:jmedgenet-2020-106866. doi:10.1136/jmedgenet-2020-106866</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2020-106866</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol 2019;76(11):1367&#x2013;1374. doi:</Citation><ArticleIdList><ArticleId IdType="doi">doi</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudette M, Hirano M, Siddique T. Current status of SOD1 mutations in familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1(2):83&#x2013;89. doi:10.1080/14660820050515377</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515377</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Nishiyama A, Warita H, Aoki M. Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. J Hum Genet 2022;13:s10038-022-01055-8. doi:10.1038/s10038-022-01055-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s10038-022-01055-8</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72(2):245&#x2013;256. doi:10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72(2):257&#x2013;268. doi:10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez-Fraga C, Magrinelli F, Hensman Moss D, et al. Expanding the spectrum of movement disorders associated with C9orf72 hexanucleotide expansions. Neurol Genet 2021;7(2):e575. doi :</Citation><ArticleIdList><ArticleId IdType="doi">doi</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 2018;14(9):544&#x2013;558. doi :</Citation><ArticleIdList><ArticleId IdType="doi">doi</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. FDA approves new treatment option for patients with ALS. Accessed August 1, 2023. fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-als</Citation></Reference><Reference><Citation>ClinicalTrials.gov. A study of BIIB067 (tofersen) initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation (ATLAS) (NCT04856982). Updated July 17, 2023. Accessed July 28, 2023. clinicaltrials.gov/ct2/show/NCT04856982</Citation></Reference><Reference><Citation>ClinicalTrials.gov. A study to assess the safety, tolerability, and pharmacokinetics of BIIB078 in adults with C9ORF72 -associated amyotrophic lateral sclerosis (NCT03626012). Updated January 14, 2022. Accessed July 28, 2023. clinicaltrials.gov/ct2/show/NCT03626012</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Study of WVE-004 in patients with C9orf72 -associated amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) (FOCUS-C9) (NCT04931862). Updated February 3, 2023. Accessed July 28, 2023. clinicaltrials.gov/ct2/show/NCT04931862</Citation></Reference><Reference><Citation>ClinicalTrials.gov. A study to assess the safety, tolerability, and effect on disease progression of BIIB105 in participants with amyotrophic lateral sclerosis (ALS) and participants with the ALS Ataxin-2 ( ATXN2 ) genetic mutation (ALSpire) (NCT04494256). Updated June 15, 2023. Accessed July 28, 2023. clinicaltrials.gov/ct2/show/NCT04494256</Citation></Reference><Reference><Citation>ClinicalTrials.gov. A study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of ION363 in amyotrophic lateral sclerosis participants with fused in sarcoma mutations (FUS-ALS) (NCT04768972). Updated March 28, 2023. Accessed July 28, 2023. clinicaltrials.gov/ct2/show/NCT04768972</Citation></Reference><Reference><Citation>Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 2017;19(3):267&#x2013;274. doi:10.1038/gim.2016.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2016.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest 2015;125(5):1767&#x2013;1779. doi:10.1172/JCI71601</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI71601</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377(2):162&#x2013;172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvam K, Benatar M, Brownlee A, et al. Amyotrophic lateral sclerosis quality measurement set 2022 update: quality improvement in neurology. Neurology 2023;101:223&#x2013;232. doi:10.1212/WNL.0000000000207166</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000207166</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330(9):585&#x2013;591. doi:10.1056/NEJM199403033300901</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996;347(9013):1425&#x2013;1431. doi:10.1016/s0140-6736(96)91680-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(96)91680-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012;2012(3):CD001447. doi:10.1002/14651858.CD001447.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, Jackson CE, Heiman-Patterson TD, Bettica P, Brooks BR, Pioro EP. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2020;21(7-8):509&#x2013;518. doi:10.1080/21678421.2020.1771734</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(7-8):610&#x2013;617. doi:10.3109/21678421.2014.959024</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017;16(7):505&#x2013;512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, et al. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve 2020;61(2):218&#x2013;221. doi:10.1002/mus.26740</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol 2022;79(2):121&#x2013;130. doi:10.1001/jamaneurol.2021.4893</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. Edaravone. Accessed May 16 2022. accessdata.fda.gov/drugsatfda_docs/label/2022/215446s000lbl.pdf</Citation></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med 2020;383(10):919&#x2013;930. doi:10.1056/NEJMoa1916945</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, et al. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. J Neurol Neurosurg Psychiatry 2022;93(8):871&#x2013;875. doi:10.1136/jnnp-2022-329024</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2022-329024</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Watkins C, Cawson M, et al. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: evaluating the impact of treatment crossover on outcomes. Muscle Nerve 2022;66(2):136&#x2013;141. doi:10.1002/mus.27569</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27569</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada. Qualifying notice for Albrioza. Accessed August 1, 2023. canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions/qualifying-notice-albrioza-253502.html</Citation></Reference><Reference><Citation>ClinicalTrials.gov. Phase III trial of AMX0035 for amyotrophic lateral sclerosis treatment (Phoenix). Updated January 6, 2023. Accessed August 22, 2023. clinicaltrials.gov/ct2/show/NCT05021536</Citation></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology 2019 10;93(24):e2294&#x2013;e2305. doi:10.1212/WNL.0000000000008620</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve 2022;65(3):291&#x2013;302. doi:10.1002/mus.27472</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27472</ArticleId></ArticleIdList></Reference><Reference><Citation>Erratum. Muscle Nerve 2022;66(4):E26&#x2013;E27. doi:10.1002/mus.27697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27697</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 2020;383(2):109&#x2013;119. doi:10.1056/NEJMoa2003715</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 2022;387(12):1099&#x2013;1110. doi:10.1056/NEJMoa2204705</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, Jafar-Nejad P, Shneider NA. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med 2022;28(1):104&#x2013;116. doi:10.1038/s41591-021-01615-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01615-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ 2020;192(46):E1453&#x2013;E1468. doi:10.1503/cmaj.191721</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.191721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5(2):140&#x2013;147. doi:10.1016/S1474-4422(05)70326-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackrivo J, Hsu JY, Hansen-Flaschen J, Elman L, Kawut SM. Noninvasive ventilation use is associated with better survival in amyotrophic lateral sclerosis. Ann Am Thorac Soc 2021;18(3):486&#x2013;494. doi:10.1513/AnnalsATS.202002-169OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202002-169OC</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73(15):1218&#x2013;1226. doi:10.1212/WNL.0b013e3181bc0141</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Calzada N, Prats Soro E, Mateu Gomez L, et al. Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation. Amyotroph Lateral Scler Frontotemporal Degener 2016;17(5-6):337&#x2013;342. doi:10.3109/21678421.2016.1165256</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1165256</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener 2017;18(suppl 1):88&#x2013;97. doi:10.1080/21678421.2017.1361445</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361445</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui F, Sun L, Xiong J, Li J, Zhao Y, Huang X. Therapeutic effects of percutaneous endoscopic gastrostomy on survival in patients with amyotrophic lateral sclerosis: a meta-analysis. PloS One 2018;13(2):e0192243. doi:10.1371/journal.pone.0192243</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0192243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairoalsindi OA, Abuzinadah AR. Maximizing the survival of amyotrophic lateral sclerosis patients: current perspectives. Neurol Res Int 2018;2018:6534150. doi:10.1155/2018/6534150</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/6534150</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2011;82(6):628&#x2013;634. doi:10.1136/jnnp.2010.211474</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.211474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg J, Bottman L, Arra EJ, Selkirk SM, Kozlowski F. Nutrition management methods effective in increasing weight, survival time and functional status in ALS patients: a systematic review. Amyotroph Lateral Scler Frontotemporal Degener 2018;19(1-2):7&#x2013;11. doi:10.1080/21678421.2017.1360355</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1360355</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C, Neuwirth C, Sommacal A, Andersen PM, Weber M. Is survival improved by the use of NIV and PEG in amyotrophic lateral sclerosis (ALS)? A post-mortem study of 80 ALS patients. PloS One 2017;12(5):e0177555. doi: 10.1371/journal.pone.0177555</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177555</ArticleId></ArticleIdList></Reference><Reference><Citation>Czell D, Bauer M, Binek J, Schoch OD, Weber M. Outcomes of percutaneous endoscopic gastrostomy tube insertion in respiratory impaired amyotrophic lateral sclerosis patients under noninvasive ventilation. Respir Care 2013;58(5):838&#x2013;44. doi:10.4187/respcare.02024</Citation><ArticleIdList><ArticleId IdType="doi">10.4187/respcare.02024</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003;74(9):1258&#x2013;1261. doi:10.1136/jnnp.74.9.1258</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.74.9.1258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 2015;86(5):496&#x2013;501. doi:10.1136/jnnp-2014-309601</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-309601</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65(8):1264&#x2013;1267. doi:10.1212/01.wnl.0000180717.29273.12</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000180717.29273.12</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwathmey K, Heiman-Patterson TD. Multidisciplinary clinics in neuromuscular medicine. Continuum (Minneap Minn) 2023;29(5, Peripheral Nerve and Motor Neuron Disorders):1585&#x2013;1594.</Citation></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135(Pt 3):847&#x2013;852. doi:10.1093/brain/awr351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2015;86(1):38&#x2013;44. doi:10.1136/jnnp-2013-306589</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna J, Couratier P, Lahmadi S, et al. Comparison of the ability of the King&#x2019;s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2021;22(7-8):478&#x2013;485. doi:10.1080/21678421.2021.1903506</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1903506</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018;17(5):423&#x2013;433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H. What if you knew the prognosis of your patients with ALS? Lancet Neurol 2018;17(5):386&#x2013;388. doi:10.1016/S1474-4422(18)30111-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30111-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskoui M, Servais L. Spinal muscular atrophy. Continuum (Minneap Minn) 2023;29(5, Peripheral Nerve and Motor Neuron Disorders):1564&#x2013;1584.</Citation></Reference><Reference><Citation>Fratta P, Nirmalananthan N, Masset L, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 2014;82(23):2077&#x2013;2084. doi:10.1212/WNL.0000000000000507</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000507</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 2006;129(Pt 6):1446&#x2013;1455. doi:10.1093/brain/awl096</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bernard E, Corcia P, et al. The French national protocol for Kennedy&#x2019;s disease (SBMA): consensus diagnostic and management recommendations. Orphanet J Rare Dis 2020;15(1):90. doi:10.1186/s13023-020-01366-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01366-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Sobue G, Doyu M, Mukai E, Hashizume Y, Mitsuma T. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression. Muscle Nerve 1995;18(3):301&#x2013;308. doi:10.1002/mus.880180306</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880180306</ArticleId></ArticleIdList></Reference><Reference><Citation>Breza M, Koutsis G. Kennedy&#x2019;s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease. J Neurol 2019;266(3):565&#x2013;573. doi:10.1007/s00415-018-8968-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8968-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Tian Y, Wu J, et al. Update on the pathogenesis, clinical diagnosis, and treatment of hirayama disease. Front Neurol 2022;12:811943. doi:10.3389/fneur.2021.811943</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.811943</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalini A, Gourie-Devi M, Thennarasu K, Ramalingaiah AH. Monomelic amyotrophy: clinical profile and natural history of 279 cases seen over 35 years (1976-2010). Amyotroph Lateral Scler Frontotemporal Degener 2014;15(5-6):457&#x2013;465. doi:10.3109/21678421.2014.903976</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903976</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto WBVR, Nunes PP, Lima E, et al. O&#x2019;Sullivan-McLeod syndrome: unmasking a rare atypical motor neuron disease. Rev Neurol (Paris) 2019;175(1-2):81&#x2013;86. doi:10.1016/j.neurol.2018.04.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2018.04.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Boruah DK, Prakash A, Gogoi BB, et al. AJNR Am J Neuroradiol 2018;39(5):974&#x2013;980. doi:10.3174/ajnr.A5577</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A5577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohno M, Takahashi H, Yagishita A, Tanabe H. &#x201c;Disproportion theory&#x201d; of the cervical spine and spinal cord in patients with juvenile cervical flexion myelopathy. A study comparing cervical magnetic resonance images with those of normal controls. Surg Neurol 1998;50(5):421&#x2013;430. doi:10.1016/s0090-3019(97)00451-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-3019(97)00451-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayana Gowda BS, Mohan Kumar J, Basim PK. Hirayama&#x2019;s disease &#x2013; a rare case report with review of literature. J Orthop Case Rep 2013;3(3):11&#x2013;14. doi:10.13107/jocr.2250-0685.107</Citation><ArticleIdList><ArticleId IdType="doi">10.13107/jocr.2250-0685.107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokumaru Y, Hirayama K. [Cervical collar therapy for juvenile muscular atrophy of distal upper extremity (Hirayama disease): results from 38 cases]. Rinsho Shinkeigaku 2001;41(4-5):173&#x2013;178.</Citation></Reference><Reference><Citation>Bohara S, Garg K, Mishra S, Tandon V, Chandra PS, Kale SS. Impact of various cervical surgical interventions in patients with Hirayama&#x2019;s disease-a narrative review and meta-analysis. Neurosurg Rev 2021;44(6):3229&#x2013;3247. doi:10.1007/s10143-021-01540-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10143-021-01540-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidd D, Howard RS, Williams AJ, Heatley FW, Panayiotopoulos CP, Spencer GT. Late functional deterioration following paralytic poliomyelitis. QJM 1997;90(3):189&#x2013;196. doi:10.1093/qjmed/90.3.189</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/90.3.189</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Hi Shing S, Chipika RH, Finegan E, Murray D, Hardiman O, Bede P. Post-polio syndrome: more than just a lower motor neuron disease. Front Neurol 2019;10:773. doi:10.3389/fneur.2019.00773</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>